Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$230 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-0 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
5.5
Industry P/E
--
EV/EBITDA
-0.1
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.3
Face value
--
Shares outstanding
7,043,990
CFO
CA$-28.26 Mln
EBITDA
CA$-31.37 Mln
Net Profit
CA$-31.64 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
| -15.5 | -8.1 | -15.8 | 2,691.7 | 89.5 | -- | -- |
|
BSE Sensex*
| 3.5 | 1.9 | 7.5 | 9.5 | 14.2 | 21.2 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
Bright Minds Biosciences Inc (DRUG)
| -61.4 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bright Minds Biosciences Inc (DRUG)
|
30.4 | 229.9 | 0.0 | -1.1 | -- | -3.3 | -- | 5.5 |
| 7.0 | 147.3 | 0.0 | -103.9 | -- | -40 | -- | 0.9 | |
| 0.4 | 40.0 | 0.0 | -31.7 | -- | -189.1 | -- | 8.5 |
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and... 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York. Address: 19 Vestry Street, New York, NY, United States, 10013 Read more
Co-Founder, CEO, President & Director
Mr. Ian McDonald
Co-Founder, CEO, President & Director
Mr. Ian McDonald
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bright Minds Biosciences Inc (DRUG) stood at $ 59 Mln as on 31-Dec-24
The share price of Bright Minds Biosciences Inc (DRUG) is $30.43 (NASDAQ) as of 21-May-2025 16:00 EDT. Bright Minds Biosciences Inc (DRUG) has given a return of 89.45% in the last 3 years.
Bright Minds Biosciences Inc (DRUG) has a market capitalisation of $ 230 Mln as on 21-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Bright Minds Biosciences Inc (DRUG) is 5.55 times as on 21-May-2025, a 8% discount to its peers’ median range of 6.02 times.
Since, TTM earnings of Bright Minds Biosciences Inc (DRUG) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bright Minds Biosciences Inc (DRUG) and enter the required number of quantities and click on buy to purchase the shares of Bright Minds Biosciences Inc (DRUG).
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York. Address: 19 Vestry Street, New York, NY, United States, 10013
The CEO & director of Mr. Ian McDonald. is Bright Minds Biosciences Inc (DRUG), and CFO & Sr. VP is Mr. Ian McDonald.
There is no promoter pledging in Bright Minds Biosciences Inc (DRUG).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
21
|
|
|
7
|
|
|
21
|
|
|
7
|
| Bright Minds Biosciences Inc (DRUG) | Ratios |
|---|---|
|
Return on equity(%)
|
-3.31
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bright Minds Biosciences Inc (DRUG) was $0 Mln.
$-2.03
(
